AAN 2021 Poster Picks – Day 3
AAN 2021 Poster Picks – Day 1
Poster 076 – Long Term Efficacy Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial
Bruce A. C. Cree, MD, PhD
Objective: Evaluate the long-term efficacy of inebilizumab in neuromyelitis optica spectrum disorder. Read More
American Academy of Neurology annual meeting – April 17-22, 2021
Wednesday, April 21 edition
Tuesday, April 20 edition
CONGRESS HIGHLIGHTS – MONDAY EDITION Read More
AAN 2021 Poster Picks – Day 3
AAN 2021 Poster Picks – Day 2
Poster 033 – Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)
Kottil W. Rammohan, MD
Objective: 9-hole peg test (9-HPT) and 25-foot walk (25-FW) function. Read More
The government of Canada has opted to prolong the second COVID-19 vaccination to 16 weeks after the first dose due to a limited vaccine supply. The decision was based on a recommendation from the National Advisory Committee on Immunization (NACI; www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html#b1). The rationale is that administering one dose to a wider population will have a greater impact on severe COVID outcomes than giving the required two doses to fewer people. This raises the question: what are the benefits and risks of this partial-immunity approach? Read More